Real-world Evidence Needs Careful Interpretation (Editorial)

Abstract

The Janus kinase (JAK) inhibitors have proven to be popular across the globe for an increasing variety of autoimmune inflammatory disorders seen in rheumatology, dermatology, and gastroenterology1. In patients with rheumatoid arthritis (RA), market share is on the rise in many countries, with 4 or 5 JAK inhibitors available or under development, and most patient categories are comprehensively studied, such as methotrexate (MTX)-naïve, MTX-inadequate responders, biological disease-modifying antirheumatic drug (bDMARD)–inadequate responders, and monotherapy, in large randomized controlled trials (RCT) that have shown efficacy with a manageable safety profile.